Newsfiscal.ai
Compass Therapeutics Presents Novel Mechanism of Action Data for CTX-10726 at SITC 2026
· Published
Article summary
Compass Therapeutics shared new preclinical data at the SITC 2026 Annual Meeting regarding the mechanism of action for its PD-1 x VEGF-A bispecific antibody, CTX-10726.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…